Windlas Biotech
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Windlas Biotech's management has articulated a positive outlook, driven by strategic investments and a diversified business model. The anticipated commercialization of Plant-6 for Oral Solids by H1 FY27 is expected to significantly enhance production capacity, which aligns with Vista's forecast of stable revenue growth. Additionally, the company's expansion into critical care and specialized therapies through its new Injectable facility is likely to bolster its competitive position and market share. R&D initiatives focusing on first-to-launch complex generics are set to further support revenue streams. Vista's financial outlook reflects stable margins and a conservatively financed balance sheet, with a low debt/equity ratio of 0.06, ensuring financial stability. The macro environment in India remains conducive, with improving manufacturing activity and favorable liquidity conditions, which may enhance operational efficiencies. However, potential headwinds include raw material supply constraints and client concentration risks. Over the next 12-24 months, key opportunities lie in expanding the customer base and leveraging structural tailwinds in Trade Generics and Exports, while watchpoints include the dynamic operating environment and the need for continued innovation
Why We Like This Stock
- Commercialization of Plant-6 for Oral Solids expected to significantly enhance production capacity
- Expansion into critical care and specialized therapies through a new Injectable facility will diversify revenue streams
- Strong focus on R&D for complex generics is likely to drive future revenue growth
Things To Watch Out For
- Raw material supply constraints may impact production and margins
- Client concentration risks could affect revenue stability
- Dynamic operating environment requires ongoing innovation and operational efficiency
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 631 | 760 | 904 | 946 | 1,085 |
| Profit Before Tax (Cr.) | 77 | 79 | 87 | 84 | 98 |
| PBT Margin | 12.2% | 10.4% | 962.4% | 8.9% | 9.1% |
| Net Profit (Cr.) | 60 | 62 | 66 | 64 | 75 |
| Earnings Per Share | 28.8 | 29.8 | 32.0 | 30.9 | 36.2 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophilized vials, and ampoules. In addition, the company offers generic drugs for respiratory, anti-diabetic, gastroenterology, cardiovascular and multivitamin, neuro anti-psychotic, diabetic care, nutraceuticals, nutritional supplement, urology, pain management, and injectable therapies. It also exports generic medicines, health supplements, and custom-branded formulations. Windlas Biotech Limited was incorporated in 2001 and is headquartered in Dehradun, India.